日本ケミファの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/02/21 | 1,617 | 1,645 | 1,617 | 1,626 | ±0 | ±0% | 3,500 |
| 2024/02/20 | 1,622 | 1,636 | 1,617 | 1,626 | +11 | +0.7% | 2,400 |
| 2024/02/19 | 1,606 | 1,619 | 1,600 | 1,615 | -1 | -0.1% | 2,900 |
| 2024/02/16 | 1,606 | 1,623 | 1,593 | 1,616 | +10 | +0.6% | 3,500 |
| 2024/02/15 | 1,610 | 1,617 | 1,595 | 1,606 | -2 | -0.1% | 8,700 |
| 2024/02/14 | 1,609 | 1,617 | 1,602 | 1,608 | -1 | -0.1% | 5,700 |
| 2024/02/13 | 1,626 | 1,626 | 1,606 | 1,609 | -2 | -0.1% | 5,200 |
| 2024/02/09 | 1,611 | 1,629 | 1,606 | 1,611 | +1 | +0.1% | 4,600 |
| 2024/02/08 | 1,627 | 1,627 | 1,610 | 1,610 | +5 | +0.3% | 3,300 |
| 2024/02/07 | 1,623 | 1,623 | 1,601 | 1,605 | -18 | -1.1% | 4,100 |
| 2024/02/06 | 1,614 | 1,629 | 1,606 | 1,623 | +25 | +1.6% | 3,400 |
| 2024/02/05 | 1,619 | 1,622 | 1,598 | 1,598 | -7 | -0.4% | 15,700 |
| 2024/02/02 | 1,598 | 1,613 | 1,597 | 1,605 | +7 | +0.4% | 4,100 |
| 2024/02/01 | 1,610 | 1,614 | 1,597 | 1,598 | -3 | -0.2% | 13,800 |
| 2024/01/31 | 1,592 | 1,612 | 1,592 | 1,601 | +12 | +0.8% | 5,100 |
| 2024/01/30 | 1,630 | 1,634 | 1,589 | 1,589 | -21 | -1.3% | 28,300 |
| 2024/01/29 | 1,628 | 1,628 | 1,608 | 1,610 | +3 | +0.2% | 2,900 |
| 2024/01/26 | 1,610 | 1,622 | 1,605 | 1,607 | -4 | -0.2% | 5,300 |
| 2024/01/25 | 1,608 | 1,628 | 1,604 | 1,611 | +8 | +0.5% | 7,300 |
| 2024/01/24 | 1,600 | 1,612 | 1,600 | 1,603 | +4 | +0.3% | 4,200 |
| 2024/01/23 | 1,609 | 1,610 | 1,599 | 1,599 | ±0 | ±0% | 6,200 |
| 2024/01/22 | 1,590 | 1,609 | 1,590 | 1,599 | +8 | +0.5% | 5,600 |
| 2024/01/19 | 1,593 | 1,600 | 1,591 | 1,591 | -3 | -0.2% | 2,600 |
| 2024/01/18 | 1,600 | 1,606 | 1,594 | 1,594 | -8 | -0.5% | 6,400 |
| 2024/01/17 | 1,601 | 1,613 | 1,600 | 1,602 | -5 | -0.3% | 5,000 |
| 2024/01/16 | 1,618 | 1,618 | 1,602 | 1,607 | -9 | -0.6% | 4,200 |
| 2024/01/15 | 1,615 | 1,621 | 1,613 | 1,616 | +1 | +0.1% | 5,300 |
| 2024/01/12 | 1,615 | 1,622 | 1,613 | 1,615 | ±0 | ±0% | 3,400 |
| 2024/01/11 | 1,615 | 1,623 | 1,613 | 1,615 | +4 | +0.2% | 4,400 |
| 2024/01/10 | 1,607 | 1,622 | 1,605 | 1,611 | -1 | -0.1% | 3,600 |
| 2024/01/09 | 1,614 | 1,616 | 1,603 | 1,612 | +12 | +0.8% | 5,800 |
| 2024/01/05 | 1,591 | 1,615 | 1,590 | 1,600 | +14 | +0.9% | 12,100 |
| 2024/01/04 | 1,580 | 1,590 | 1,577 | 1,586 | +25 | +1.6% | 5,300 |
| 2023/12/29 | 1,575 | 1,577 | 1,558 | 1,561 | -14 | -0.9% | 3,900 |
| 2023/12/28 | 1,566 | 1,579 | 1,557 | 1,575 | +9 | +0.6% | 3,900 |
| 2023/12/27 | 1,552 | 1,570 | 1,552 | 1,566 | +14 | +0.9% | 6,300 |
| 2023/12/26 | 1,567 | 1,569 | 1,550 | 1,552 | -12 | -0.8% | 12,600 |
| 2023/12/25 | 1,577 | 1,580 | 1,557 | 1,564 | -18 | -1.1% | 13,200 |
| 2023/12/22 | 1,600 | 1,600 | 1,577 | 1,582 | -18 | -1.1% | 17,100 |
| 2023/12/21 | 1,606 | 1,607 | 1,600 | 1,600 | -6 | -0.4% | 4,600 |
| 2023/12/20 | 1,611 | 1,613 | 1,606 | 1,606 | -6 | -0.4% | 3,800 |
| 2023/12/19 | 1,616 | 1,616 | 1,612 | 1,612 | -2 | -0.1% | 1,300 |
| 2023/12/18 | 1,618 | 1,618 | 1,611 | 1,614 | -3 | -0.2% | 1,000 |
| 2023/12/15 | 1,619 | 1,620 | 1,613 | 1,617 | -2 | -0.1% | 5,000 |
| 2023/12/14 | 1,619 | 1,623 | 1,615 | 1,619 | +1 | +0.1% | 2,200 |
| 2023/12/13 | 1,620 | 1,622 | 1,618 | 1,618 | -2 | -0.1% | 3,100 |
| 2023/12/12 | 1,623 | 1,624 | 1,619 | 1,620 | -1 | -0.1% | 4,600 |
| 2023/12/11 | 1,634 | 1,634 | 1,619 | 1,621 | -12 | -0.7% | 5,100 |
| 2023/12/08 | 1,656 | 1,656 | 1,628 | 1,633 | +8 | +0.5% | 7,400 |
| 2023/12/07 | 1,640 | 1,640 | 1,620 | 1,625 | -9 | -0.6% | 3,900 |
51～
100
件表示中 / 3450件
類似銘柄と比較する
現在ご覧いただいている「日ケミファ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 日ケミファ | 160,100円 | -2.6% | - | 3.12% | - | 0.31倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
| シンバイオ | 16,300円 | -53.1% | - | 0.00% | - | 1.08倍 |
|
他社から新薬候補導入し開発、製品化。抗ウイルス薬「ブリンシドフォビル（ＢＣＶ）」開発注力 |
| カイオム | 12,600円 | +2.6% | - | 0.00% | - | 6.16倍 |
|
独自の抗体作製技術を持つ理研発の創薬ベンチャー。医薬品候補抗体導出と技術供与が収益源 |
| ノイルイミューン | 15,400円 | -5.1% | - | 0.00% | - | 1.17倍 |
|
独自技術用いたＣＡＲ－Ｔ細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
| ＤＥＬＴＡ－Ｐ | 72,900円 | - | - | 0.00% | - | 14.96倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
市場注目の銘柄
チャート関連のコラム
